PennyPerformers.com: "Penny Stocks that Perform" picks are: ACOR, AMGN, APDN, ELRA, ETLY, SNPS

The Newest and Revolutionary Technology for Increasing Investor Visability.

REAL Awareness for REAL Companies.

Click below for a full demonstration.

http://newmediaadvisors.info/newmedia.swf

Sign-up for our FREE Stock Alerts AND NEWSLETTER at www.pennyperformers.com

Apr 16, 2009 -- Acorda Therapeutics, Inc. (NASDAQ: ACOR | Quote | Chart | News | PowerRating) today announced that Anthony Caggiano, M.D., Ph.D., Vice President, Preclinical Development, will present at the upcoming New York Biotechnology Association (NYBA) Annual Meeting on Monday, April 20, 2009 at 9:20 a.m. Eastern Time at the Marriott Marquis Hotel in New York, NY. Dr. Caggiano will present an overview of Acorda's clinical and preclinical pipeline as part of the NYBA Bioscience Industry Showcase.

For information and registration for the Showcase, please contact Patricia Wadington at New York Biotechnology Association, pwadington@nyba.org, 631-444-8895. Investor and strategic partner registration for the Showcase is complimentary, but please note that complimentary registration does not include concurrent NYBA Annual Meeting events, such as the Plenary Luncheon or Gala Reception. Registration for these events may be purchased separately.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

About New York Biotechnology Association

NYBA is the leading advocate for advancing the success of the biotechnology industry in New York State and is its main representative to policy makers, the media and the communities in which we work. NYBA's mission is to support the development and growth of New York's biotechnology industry, and to serve our members and the biotechnology community by providing a network for information exchange, shared services and collective action. NYBA's membership comprises bioscience companies, world-class research institutions and related professional services. Under the banner of The Cures Start Here(R), our goal is to amplify the success New York has had and continues to have in discovering major medical advances and growing a vibrant biotech industry.

April 16, 2009 -- Amgen Inc. (NASDAQ: AMGN | Quote | Chart | News | PowerRating) today announced that results from several preclinical studies investigating potential new cancer agents will be presented at the 2009 American Association for Cancer Research (AACR) Annual Meeting in Denver between April 18-22, 2009.

Data will be presented on investigational compounds AMG 386, a peptibody that binds to and inhibits angiopoietins 1 and 2; AMG 479, a fully human monoclonal antibody antagonist of the type 1 insulin-like growth factor receptor (IGF-1R) and AMG 102, a fully human monoclonal antibody antagonist of HGF, the ligand for the c-Met receptor.

"The data being presented at this meeting further our biologic understanding of these novel compounds and pathways, and inform our thinking regarding opportunities to develop predictive or prognostic biomarkers," said C. Glenn Begley, M.D., vice president, Global Hematology and Oncology Research at Amgen. "This is an exciting year for our oncology therapeutics pipeline, as results from a number of clinical programs become available."

Selected Abstracts of Interest -- Assessment of angiogenesis inhibitors in the retinopathy of prematurity model in mice Overview: Examined the inhibition of the VEGF/VEGFR pathway with AMG 273 and the inhibition of the angiopoietin/Tie2 pathway with AMG 386 Lead author: Estrada J.

Abstract No. 140 (Sunday, April 19, 2009, 8:00 am - 12:00 pm)

-- Involvement of the CSF-1/CSF-1R interaction in the control of angiogenesis Overview: Two different neutralizing rat anti murine CSF-1R monoclonal antibodies (mAb), M279 and AFS98 were evaluated for their effect on mouse corneal angiogenesis and corneal macrophage recruitment in vivo Lead author: Liu H.

Abstract No. 1106 (Sunday, April 19, 2009, 1:00 pm - 5:00 pm)

-- Complementary and opposing effects of angiopoietin-1 and angiopoietin-2 inhibitors on tumor blood vessels and normalization Overview: Aimed to elucidate the effects of Angiopoietin (Ang) 1 and Ang2 on the tumor vasculature of a human colon carcinoma model (Colo205) using peptide-Fc fusion proteins (peptibodies) specifically targeting Ang1 (mL4-3) or Ang2 (L1-7(N)) alone or in combination Lead author: Falcon B.

Abstract No. 1996 (Monday, April 20, 2009, 9:40 am - 9:55 am)

-- AMG 479, a novel IGF-1R antibody, inhibits endometrial cancer cell proliferation through disruption of the P13K/Akt and MAPK pathways Overview: Evaluated the effect of a novel antibody to the IGF-1R (AMG 479) on cell proliferation and expression of key targets involved in IGF-1R signaling in endometrial cancer cells Lead author: Mendivil A.

Abstract No. 2804 (Monday, April 20, 2009, 1:00 pm - 5:00 pm)

-- AMG 479, a fully human anti-IGF-1R monoclonal antibody, inhibits rapamycin-induced Akt activation in sarcoma cell lines Overview: Evaluated whether AMG 479 could inhibit this feedback-loop mechanism and thus increase the efficacy of rapamycin and its analogs (mTOR inhibitors).

Lead author: Beltran P.

Abstract No. 2805 (Monday, April 20, 2009, 1:00 pm - 5:00 pm)

-- Dual targeting of the receptor tyrosine kinase EGFRvIII and HGF:c-Met signaling in models of glioblastoma multiforme (GBM) Overview: Examined the effect of combining a fully human neutralizing antibody targeting the HGF:c-Met axis (AMG 102), with a fully human antibody binding to the EGFR and EGFRvIII (panitumumab) to overcome resistance to HGF:c-Met based therapeutic strategies in GBM Lead author: Johns T.

Abstract No. 2044 (Monday, April 20, 2009, 1:10 pm - 1:25 pm)

-- Antagonistic antibodies to c-fms block c-fms-mediated activities, reduce tumor-associated macrophages and decrease tumor growth in preclinical models Overview: Antagonistic antibodies to c-fms were evaluated for their effects on monocytic cell function in vitro and tumor-associated macrophages (TAMs) and tumor growth in vivo Lead author: Bonham L.

Abstract No. 2077 (Monday, April 20, 2009, 3:40 pm - 3:55 pm)

-- Erythropoietin Receptor (EpoR) Was Expressed at Low to Undetectable Levels in Tumor Cell Lines: Expression Was Not Regulated by Hypoxia and No Epo-Induced Downstream Signaling Was Detectable Overview: EpoR, mRNA and protein expression were surveyed in 67 tumor-derived cell lines from ovary, breast, head and neck, lung, brain, prostate, cervix, liver, colon and blood Lead author: Swift S.

Abstract No. 4283 (Tuesday, April 21, 2009, 1:00 pm - 5:00 pm)

Amgen Launches Educational Interactive Angiogenesis Website

Amgen would like to invite healthcare professionals to visit http://angiogenesis.amgen.com, where the science of angiogenesis comes to life. Angiogenesis, a fundamental mechanism in normal development and cancer, involves multiple cellular regulators that include the angiopoietins, the VEGF family and other regulators. Amgen has developed an interactive website that will provide users with a cinematic experience through which to view the process of tumor vessel growth.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

Apr 16, 2009 -- Applied DNA Sciences, Inc. (OTCBB: APDN), a provider of DNA security solutions, announced today that it has opened an authentication laboratory in Huddersfield, Yorkshire, UK. This laboratory will produce forensic evidence of originality and product identity, and will be operated by APDN's subsidiary, Applied DNA Sciences Europe Ltd. Located at the Textile Centre of Excellence, this new facility will be utilized to service all of APDN's business, including the immediate goals of expanding both the SigNature(R) DNA and BioMaterial GenoTyping(R) Textile programs, and providing authentication services for the Cash-In-Transit industry.

Tony Benson, Risk Director for Loomis UK, stated, "DNA stands strongly on its own merit as the ultimate reality check. Loomis uses SigNature DNA in its cash boxes to ensure that when cash is stolen it is stained with the DNA and that criminals who come into contact with the cash are also stained with the DNA. This is a significant deterrent to criminals, as they stand a far greater chance of being convicted if they attempt a robbery against Loomis."

Loomis chose to use SigNature DNA because it offers far superior qualities in comparison to other taggants. Loomis won an award for its use of SigNature DNA from the International Association of Currency Affairs at their recent conference in Prague for "Best New Product, Process or Currency System."

DNA is a form of forensic evidence trusted by police and recognized by international courts around the world. Once it is applied onto any surface, DNA resists removal. SigNature DNA is distinct from every other taggant in the market because every mark is unique, cannot be copied, or re-engineered. SigNature DNA withstands testing at physicochemical extremes and can be authenticated in a diverse range of substrates.

"SigNature DNA provides Loomis' customers and employees with the 'peace of mind' they deserve and assists the UK Police in detecting crime and convicting criminals," commented Tony Benson.

SigNature DNA is combined with "degradation" dyes that leave a visible stain on currency which is the hallmark used by banks to remove the note from circulation. Included in the DNA-dye complex are invisible dyes used by the UK Police to verify DNA-marked notes. SigNature DNA is sprayed onto currency in ATMs or Cash Transport boxes whenever they are disturbed.

Expansion into the UK will help APDN better serve its growing international market throughout Europe and support a number of new corporate objectives. APDN will begin immediately testing recovered bank notes to assist UK Police in prosecuting apprehended suspects to the fullest extent of the law.

Bill Macbeth, Managing Director, Textile Centre of Excellence, commented, "We are very pleased to welcome Applied DNA Sciences to this facility, and I congratulate the team on successfully growing their business and reputation in DNA Authentication here in Yorkshire."

Fiona Macleod, the UK Vice Consul Trade and Investment stated, "We are impressed with the technology that Applied DNA Sciences provides to help the UK economy, from Cash-In-Transit, right through to ensuring Made-In-Britain products are genuine. UK Trade and Investment, together with Yorkshire Forward, welcome Applied DNA Sciences to the UK and look forward to assisting them with future developments."

About Loomis

Loomis offers products and services that provide complete cash logistics solutions for financial institutions, retailers and other commercial enterprises. Loomis is present in twelve European countries and in the USA and has just over 20,000 employees. Loomis, is a world leading Cash Handling Organisation and in the UK handles over GBP 150 billion in cash annually.

Apr 16, 2009 -- Elray Resources, Inc. (OTCBB: ELRA), a technically-driven mining and exploration company today announced that it is ahead of schedule for the completion of its mining study for its Zircon Sands Project.

Elray Resources Inc. has a 50% interest in a highly promising zircon sands mining project in Central Kalimantan, Indonesia with PT. Indo Imperial Resources Tambang, who have been successfully operating the project on a small scale for the last two years. PT Indo Imperial Resources Tambang is looking to Elray Resources to provide the resources and technical expertise required to take production to the next level.

Data available from the project demonstrates that the zircon is of a very high quality and is commanding premium prices. As a result, Elray Resources is in the process of doing a study on the current operating Zircon mining project. The study is covering drilling / test pitting programs, trace element analysis, metallurgical testing for plant specification and design, and financial modelling. By-product opportunities, including for gold, illmenite and rutile are also being investigated as a priority.

China has recognized the high quality of the zircon currently being delivered against contracts by this project. The project requires low capital expenditure to increase production as demanded by China and Elray fully expects the use of new more efficient recovery technologies to enable rapid revenue stream development and attractive returns.

About Elray Resources, Inc.

Elray Resources, Inc. is a junior exploration and development Corporation which has successfully accumulated a portfolio of highly prospective, heavily mineralized mining tenements in South East Asia. Elray Resources, Inc.'s, primary objective is to source projects, conduct geological assessments and seek Joint Venture partners to develop the properties.

Apr 16, 2009 -- ECOtality, Inc. (OTCBB: ETLY), a leader in clean electric transportation and storage technologies, today announced it has entered into a commitment with Nissan North America and Maricopa Association of Governments (MAG) to facilitate the establishment of electric vehicle (EV) charge infrastructure throughout Arizona's Maricopa County. In conjunction with the anticipated 2010 launch of Nissan's zero-emission electric vehicle, ECOtality will initiate its EV Micro-Climate program in the Phoenix region to promote sensible policies, intelligent deployment of charge infrastructure, and strong public awareness to foster the successful consumer adoption of grid-connected electric vehicles. With a similar partnership previously announced in Pima County, ECOtality plans to link the Phoenix and Tucson metro areas by implementing strategic fast-charge stations along Interstate 10 (I-10) to create the first true implementation of an EV Corridor in North America.

"By establishing the Phoenix and Tucson metro areas as EV Micro-Climates, Arizona is providing a blueprint for how to intelligently build a statewide EV infrastructure: Make major population areas an EV Micro-Climate and connect them with EV Corridors enabled by fast-charging," said Jonathan Read, president and CEO, ECOtality. "ECOtality's proven EV infrastructure experience, our strong familiarity with the transportation and political environment of Arizona, as well as our industry-leading fast-charge technology, exceptionally positions ECOtality to facilitate the roll-out of EV infrastructure throughout Arizona. We look forward to working closely with the appropriate organizations in Arizona to ensure the implementation of charging infrastructure is done as efficiently and intelligently as possible."

ECOtality, Nissan and MAG have committed to form EV Micro-Climate Working Groups that will unite strategic organizations in Maricopa County to streamline the roll-out of charge infrastructure to support the public launch of grid-connected vehicles. In conjunction with these efforts, Nissan has committed to make available a supply of electric vehicles to the Region's public and private fleets in 2010, the year Nissan's electric vehicle will be ready for the commercial market.

"Nissan through the Renault-Nissan Alliance has committed to being a global leader in zero-emission vehicles," said Dominique Thormann, senior vice president, administration and finance, Nissan North America. "Nissan, the Maricopa Association of Governments, and ECOtality share in the belief that the introduction and expansion of electric vehicles is one of the best solutions to reducing CO2 emissions. This partnership is an important step in making zero emissions a reality in Arizona."

While the implementation of public charge infrastructure is planned to support the initial launch of Nissan's zero-emission vehicle, public and commercial charging stations in the Maricopa region will meet all EV charging system standards (including the SAE J1772 Electric Vehicle Conductive Charge Coupler Specifications) and will be universally compatible with the new grid-connected vehicles of other major automakers.

"This partnership with Nissan and ECOtality enables us to consider strategic initiatives to support the introduction of electric vehicles in our region and to encourage individuals to incorporate green technology into their lives," said MAG Chair Peggy Neely, a Phoenix councilwoman. "Our goal is to work to develop regional policies that improve the quality of life in our region."

About ECOtality, Inc.

ECOtality, Inc., headquartered in Scottsdale, Arizona, is a leader in clean electric transportation and storage technologies. Through innovation, acquisitions, and strategic partnerships, ECOtality accelerates the market applicability of advanced electric technologies to replace carbon-based fuels.
April 15, 2009 -- Synopsys, Inc. (Nasdaq: SNPS), a world leader in software and IP for semiconductor design and manufacturing, today announced that it has enhanced its DesignWare(R) IP for the ARM(R) AMBA(R) 3 AXI(TM) interconnect with the industry's first hybrid architecture implementation, enabling dedicated high-performance and shared low-performance channels to be combined within a single AMBA 3 AXI on-chip interconnect. This new architecture, available in synthesizable source RTL, allows designers to configure the bus fabric to eliminate unnecessary logic within the design, thereby reducing area, power consumption, and overall routing congestion. The hybrid architecture is ideal for system-on-chip (SoC) designs that use a native AMBA 3 AXI interconnect. It also reduces the area impact for SoC designs transitioning from an AMBA 2.0 AHB(TM) to an AMBA 3 AXI-based architecture.

As demands on system performance continue to increase, the effective control of bandwidth allocation for SoC peripherals becomes increasingly important. The bandwidth requirements for each master-to-slave link within a system can vary widely. Traditional off-the-shelf bus architectures consist of either a single shared bus that services all master and slave devices, or dedicated buses that service specific master and slave devices. These bus architectures do not give designers the ability to configure the interconnect to accommodate individual component requirements. The new hybrid architecture implemented in the DesignWare IP for the AMBA 3 AXI interconnect provides designers with a choice of connecting the master-to-slave link through either a shared or dedicated bus within a single AMBA 3 AXI on-chip bus interconnect. This flexibility helps designers reduce the number of dedicated buses and wires in the system, alleviating routing congestion, minimizing area and lowering power consumption. Furthermore, the architecture eases timing closure by allowing for greater control of the critical paths throughout the bus interconnect.

In a recent case study using the Galaxy(TM) Implementation Platform, Synopsys configured the DesignWare IP for AMBA 3 AXI interconnect fabric consisting of 10 master and 10 slave ports. The hybrid architecture allows the low bandwidth master-slave links of the dedicated bus to be replaced with a shared bus, while keeping the high-bandwidth master-slave links as dedicated buses. With this implementation, Synopsys was able to reduce the number of wires by 52 percent, area by 30 percent, and power consumption by 30 percent when compared with Synopsys' traditional DesignWare IP for the AMBA 3 AXI interconnect fabric without the hybrid architecture.

The hybrid architecture has been verified using Synopsys DesignWare Verification IP for the AMBA 3 AXI interconnect, which has earned the ARM AMBA 3 Assured(TM) logo certification. Certification lowers integration risk and gives designers confidence that their AMBA 3 AXI interconnect-based designs using the DesignWare IP will accurately adhere to the AMBA 3 AXI protocol specifications as defined by ARM. The DesignWare IP for the AMBA 3 AXI interconnect provides internal piping options, allowing designers to balance the operating frequency and latency requirements without incurring a throughput penalty.

"The AMBA 3 AXI protocol is one of the most popular on-chip interconnects for high performance SoCs, and Synopsys' new hybrid architecture will help extend the use of this interconnect into next-generation applications with improved performance and area," said John Koeter, vice president of marketing for the Solutions Group at Synopsys. "As designers migrate to the high- performance AMBA 3 AXI on-chip interconnect, they can rely on Synopsys' established history in providing high-quality, silicon-proven AMBA IP to help them efficiently deliver advanced SoCs."

Availability

The hybrid architecture in the DesignWare IP for the AMBA 3 AXI interconnect is available now to early adopters. The IP is provided in synthesizable source RTL, as part of Synopsys' broad portfolio of comprehensive, silicon-proven IP solutions for the most widely used standards- based interfaces such as PCI Express, USB, DDR, SATA and Ethernet. General availability is scheduled for Q3 2009.

About DesignWare IP

Synopsys offers a broad portfolio of high-quality, silicon-proven digital, mixed-signal and verification IP for system-on-chip designs. As a leading provider of connectivity IP, Synopsys delivers the industry's most comprehensive solutions for widely used protocols such as USB, PCI Express, SATA, Ethernet and DDR. In addition to connectivity IP, Synopsys offers SystemC transaction-level models to build virtual platforms for rapid, pre- silicon development of software. With a robust IP development methodology, extensive investment in quality and comprehensive technical support, Synopsys enables designers to accelerate time-to-market and reduce integration risk.

About Synopsys

Synopsys, Inc. (NASDAQ:SNPS) is the world leader in electronic design automation (EDA), supplying the global electronics market with the software, intellectual property (IP) and services used in semiconductor design and manufacturing. Synopsys' comprehensive, integrated portfolio of implementation, verification, IP, manufacturing and field-programmable gate array (FPGA) solutions helps address the key challenges designers and manufacturers face today, such as power and yield management, software-to- silicon verification and time-to-results. These technology-leading solutions help give Synopsys customers a competitive edge in bringing the best products to market quickly while reducing costs and schedule risk. Synopsys is headquartered in Mountain View, California, and has more than 60 offices located throughout North America, Europe, Japan, Asia and India.

About PennyPerformers.com

PennyPerformers.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

Penny Performers email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Penny Performers Report home page at www.PennyPerformers.com and select the "join now" button.

Join us at www.PennyPerformers.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. PennyPerformers.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyPerformers.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. PennyPerformers.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), PennyPerformers.com is owned and operated by PennyPerformers.com. Neither PennyPerformers.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since PennyPerformers.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in PennyPerformers.com statements and opinions and such statements and opinions cannot be considered independent. PennyPerformers.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. PennyPerformers.com services are often paid for using free-trading shares. PennyPerformers.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.PennyPerformers.com/disclaimer.htm

CONTACT: PennyPerformers.com
e-mail: info@pennyperformers.com
WWW: http://www.PennyPerformers.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on Amgen Inc (AMGN) AMGN. Amgen Inc (AMGN) has Short Term PowerRatings at TradingMarkets. Details on Amgen Inc (AMGN) Short Term PowerRatings is available at This Link.

For full details on Synopsys Inc (SNPS) SNPS. Synopsys Inc (SNPS) has Short Term PowerRatings at TradingMarkets. Details on Synopsys Inc (SNPS) Short Term PowerRatings is available at This Link.

For full details on Acorda Therapeutics Inc (ACOR) ACOR. Acorda Therapeutics Inc (ACOR) has Short Term PowerRatings at TradingMarkets. Details on Acorda Therapeutics Inc (ACOR) Short Term PowerRatings is available at This Link.

For full details on (ETLY) ETLY. (ETLY) has Short Term PowerRatings at TradingMarkets. Details on (ETLY) Short Term PowerRatings is available at This Link.

For full details on (APDN) APDN. (APDN) has Short Term PowerRatings at TradingMarkets. Details on (APDN) Short Term PowerRatings is available at This Link.

For full details on (ELRA) ELRA. (ELRA) has Short Term PowerRatings at TradingMarkets. Details on (ELRA) Short Term PowerRatings is available at This Link.

For full details on (ELRAE) ELRAE. (ELRAE) has Short Term PowerRatings at TradingMarkets. Details on (ELRAE) Short Term PowerRatings is available at This Link.